Back to Blog
Cmp nucleo forte plm6/24/2023 ![]() Usage of Nucleo CMP Forte in the combined treatment of patients has more expressed positive influence on problems with walking. It has been prescribed for peripheral nervous system disorders, such as lum-bosciatalgia, diabetic or alcoholic polyneuropathy, or trigeminal neuralgia. We used non-parametric test χ 2 to evaluate efficacy of therapy. Nucleo CMP Forte ® is a nucleotide-based drug consisting of cytidinemonophosphate, uridinemonophosphate, uridin-ediphosphate and uridinetriphosphate. Patients filled questionnaire of life quality EQ-5D-3L (Ukraine 2004, EuroQol) on the first and tenth day of treatment. ![]() They were compared into two groups: A 30 patients received standard treatment, B 29 diabetics additionally were taken Nucleo CMP Forte (1 capsule three times a day). Inicio / Vademécum actuamed / Buscar / NUCLEO C.M.P. Methods: It was examined 59 (41≧9 years old) patients with type 2 DM and DPNP. Núcleo CMP Forte, citidin, uridin, cápsulas indicadas en el tratamiento de neuropatías de origen osteoarticular, metabólico, neuralgias. The aim: To evaluate the efficacy of Nucleo CMP Forte (Cytidine 5- disodium monophosphate and Uridine 5- trisodium triphosphate) in the combined treatment of patients with DPNP. New medications in DPNP have to be studied. Nucleo CMP Forte pharmaceutical companies: Pharmaceutical companies are drug manufacturing companies that help in complete development of the drug from the background research to formation, clinical trials, release of the drug into the market and marketing of the drug. Introduction: The protocols of medical care of diabetic peripheral neuropathy (DPNP) are developed but positive effect cannot be achieved in all patients.
0 Comments
Read More
Leave a Reply. |